Ribupatide, a weekly GLP-1 and GIP injection, led to 10.7% to 17.7% weight loss in a China phase 3 trial

| Trial results

A phase 3 trial of ribupatide (HRS9531, KAI-9531), a once-weekly injection that works on the GLP-1 and GIP receptors, has been published in JAMA. In GEMINI-1, 567 adults in China without diabetes lost an average of 10.7%, 16.4% or 17.7% of their body weight over 48 weeks on 2, 4 or 6 mg, compared with 1.4% on placebo. The medicine was developed by Jiangsu Hengrui. Kailera Therapeutics holds the rights outside Greater China.

What the paper reports

QuestionWhat the paper reports
Who took part567 adults at 55 sites in China, without diabetes, with a BMI of at least 28, or at least 24 with a weight-related condition. 142 got 2 mg, 141 got 4 mg, 141 got 6 mg and 143 got placebo. The average person was 34 years old with a BMI of 33.3.
Average weight change at week 48Down 10.7% at 2 mg, 16.4% at 4 mg and 17.7% at 6 mg, versus 1.4% on placebo. This is the treatment-policy view, which counts everyone in the group they were assigned to, including people who stopped early.
Common side effectsNausea in 16.2% to 27.0% across the three doses (placebo 4.9%), vomiting in 14.1% to 24.1% (placebo 2.1%) and diarrhea in 29.6% to 35.5% (placebo 7.0%).
Stopped treatment because of a side effect1 of 142 people (0.7%) at 2 mg, 1 of 141 (0.7%) at 4 mg and 2 of 141 (1.4%) at 6 mg. None on placebo.
DeathsNone in any group.

What it does not show

The trial compared ribupatide with placebo only. It did not compare it with tirzepatide or any other medicine, and the design differs from the large tirzepatide trials: a younger, lighter group in China, a 48-week length, and a different way of stepping up the dose. For those reasons the percentages should not be lined up against other trials as if they were a head-to-head result.

Four hundred twenty-four people took ribupatide. That is enough to show common effects but not rarer ones, and 48 weeks says nothing about what happens over years or after stopping.

Where it stands

China's regulator accepted a marketing application for ribupatide in September 2025, and no approval was found as of November 16, 2026. It is not approved anywhere that the Atlas could find. The medicine page has the dated company timeline, the oral tablet version and the full list of what is still unknown: ribupatide profile. PeptideBlog.net has a separate analysis of the same paper, Ribupatide in JAMA: what GEMINI-1 shows, and what a 567-person China trial cannot.

Worth knowing: This is one placebo-controlled trial run in China. It shows how ribupatide compares with placebo, not how it compares with other weight-loss medicines.

Related: Ribupatide medicine page | Tirzepatide medicine page | Mazdutide medicine page

Source: GEMINI-1 randomized clinical trial of ribupatide in adults with obesity, JAMA, online November 15, 2026 Journal article. ClinicalTrials.gov record NCT06396429 Trial registry.

More news

All news | What changed lately | Subscribe by RSS | Lilly tracker | Novo Nordisk tracker | About the Atlas

Not medical advice. News items describe what was announced or published. They do not say whether a medicine is right for you. A licensed clinician who knows your history does.